TREATMENT RESISTANT DEPRESSION DEVELOPMENT FROM MAJOR DEPRESSIVE DISORDER: A CLAIMS DATABASE ANALYSIS IN JAPAN

被引：2
|
作者：
Tsukazawa, S. K. [1 ]
Fife, D. [2 ]
Shimamoto, K. [3 ]
Mahlich, J. [1 ]
机构：
[1] Janssen Pharmaceut KK, Tokyo, Japan
[2] Janssen, Titusville, NJ USA
[3] MediStatLab, Tokyo, Japan
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.08.519
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMH25
引用
收藏
页码：A843 / A843
页数：1
相关论文
共 50 条
  • [31] Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
    Rong, Carola
    Park, Caroline
    Rosenblat, Joshua D.
    Subramaniapillai, Mehala
    Zuckerman, Hannah
    Fus, Dominika
    Lee, Yena L.
    Pan, Zihang
    Brietzke, Elisa
    Mansur, Rodrigo B.
    Cha, Danielle S.
    Lui, Leanna M. W.
    McIntyre, Roger S.
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2018, 15 (04):
  • [32] Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis
    Geneviève Gauthier
    Annie Guérin
    Maryia Zhdanava
    William Jacobson
    George Nomikos
    Elizabeth Merikle
    Clément François
    Vanessa Perez
    BMC Psychiatry, 17
  • [33] Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis
    Gauthier, Genevieve
    Guerin, Annie
    Zhdanava, Maryia
    Jacobson, William
    Nomikos, George
    Merikle, Elizabeth
    Francois, Clement
    Perez, Vanessa
    BMC PSYCHIATRY, 2017, 17
  • [34] Treatment resistant depression incidence and prevalence using the French nationwide claims database
    Bosco-Levy, Pauline
    Grelaud, Angela
    Blin, Patrick
    Astruc, Bernard
    Falissard, Bruno
    Llorca, Pierre-Michel
    Bernard, Marie-Agnes
    Lassalle, Regis
    Moore, Nicholas
    Droz-Perroteau, Cecile
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (02) : 169 - 177
  • [35] DIRECT COSTS OF PATIENTS WITH TREATMENT RESISTANT AND NON-TREATMENT RESISTANT MAJOR DEPRESSIVE DISORDER
    Ivanova, J.
    Birnbaum, H. G.
    Kidolezi, Y.
    Subramanian, G.
    Stensland, M. D.
    Khan, S. A.
    VALUE IN HEALTH, 2009, 12 (03) : A177 - A177
  • [36] TREATMENT PATTERNS AND CHARACTERISTICS OF PEOPLE WITH NEWLY DIAGNOSED MAJOR DEPRESSIVE DISORDER ACROSS THE KOMODO CLAIMS DATABASE 2018-2020
    Mohandas, A.
    Tak, C. R.
    Kavelaars, R.
    VALUE IN HEALTH, 2022, 25 (12) : S220 - S221
  • [37] Psychotic Features in Patients With Major Depressive Disorder: A Report From the European Group for the Study of Resistant Depression
    Dold, Markus
    Bartova, Lucie
    Kautzky, Alexander
    Porcelli, Stefano
    Montgomery, Stuart
    Zohar, Joseph
    Mendlewicz, Julien
    Souery, Daniel
    Serretti, Alessandro
    Kasper, Siegfried
    JOURNAL OF CLINICAL PSYCHIATRY, 2019, 80 (01) : E1 - E7
  • [38] The cost-effectiveness of paroxetine in treatment of major depressive disorder in Japan
    Nakahara, N
    Kamae, I
    Yanagisawa, S
    VALUE IN HEALTH, 2004, 7 (06) : 780 - 780
  • [39] Treatment-resistant depression and risks of suicide and natural mortality in Taiwanese elderly patients with major depressive disorder
    Cheng, Chih-Ming
    Liu, Mu-N
    Tsai, Chia-Fen
    Tsai, Shih-Jen
    Chen, Mu-Hong
    INTERNATIONAL PSYCHOGERIATRICS, 2024, 36 : 95 - 95
  • [40] Early onset of depression and treatment outcome in patients with major depressive disorder
    Herzog, David P.
    Wagner, Stefanie
    Engelmann, Jan
    Treccani, Giulia
    Dreimueller, Nadine
    Mueller, Marianne B.
    Tadic, Andre
    Murck, Harald
    Lieb, Klaus
    JOURNAL OF PSYCHIATRIC RESEARCH, 2021, 139 : 150 - 158
12345